Peng Li: Immunogenicity Assessment during the development of antibody therapeutics
132 بار بازدید -
11 ماه پیش
-
Dr. Peng Li is a
Dr. Peng Li is a Cancer Immunology Scientist at Eisai in Japan. Dr. Peng moved from his home China, Xi’an to Japan in 2010 to pursue his education and has obtained his Ph.D at the University of Tokyo in 2017 where he studied the Immunology of inflammatory bowel disease at the department of Applied Biological Chemistry. During his Ph.D, he went on as a visiting research fellow at the University of Nottingham, UK in 2016 to research Chronic obstructive pulmonary disease (COPD) at the medical school. Following his Ph.D, he completed his postdoc at Kyoto University Medical School in 2019 working on cancer immunology research in Honjo’s Lab that won the 2018 Nobel Prize in physiology or medicine. He then joined Eisai in 2019 as a scientist in cancer immunology research. In this talk, Dr. Li will be sharing with us their strategy for immunogenicity risk assessment for the development of antibody therapeutics that includes the use of ProImmune's ProScern DC-T cell assay.
11 ماه پیش
در تاریخ 1402/07/06 منتشر شده
است.
132
بـار بازدید شده